Citations

Mayo Clinic

Clear

44 citation(s) found for "Azar, J".

The Sport Publication Observational Research Tool (SPORT): An Objective Tool to Score the Methodological Quality of Observational Clinical Sports Medicine Research
Kuhn, Andrew W. , Inclan, Paul M. , Haider, Ameer A. , Christy, Michele, Dunn, Warren, Alberton, Laura A. , Allen, Christina, Anderson, Kyle, Andrews, James, Azar, Fred, Baer, Geoffrey S. , Banffy, Michael B. , Bedi, Asheesh , Brockmeier, Stephen F., Brophy, Robert H. , Bush‐Joseph, Charles A., Carey, James R. , Carter, Thomas, Cohen, Steven, Farrow, Lutul D. , Flanigan, D. Preston, Franklin, Corinna C. , Hame, Sharon L. , Ioannis, Terzidis, Joseph, Sheeba, Kenter, Keith , Koh, Jason R., Krych, Aaron, LeClere, LT Lance, Levy, Bruce, McAllister, David, Morganti, Christina, Musahl, Volker , Nelson, Bradley , Noyes, Frank, Owens, COL Brett D., Pace, Lee, Paulos, Lonnie E., Rodeo, Scott, Safran, Marc, Savoie, Felix H. , Shelbourne, Donald K., Sherman, Seth L. , Singer, Ken, Smith, Matthew, Sonnery-Cottet, Bertrand, Spiker, Andrea M. , Stuart, Michael, Warren, Russell, Wittstein, Jocelyn R. , Wolcott, Michelle L., Wright, Rick, Matava, Matthew J. , Sherman, Seth L. , Kuhn, Andrew W , Dunn, Warren R., Brockmeier, Stephen F. , Brophy, Robert H. , Carey, James, Cohen, Steven B. , Flanigan, David, Krych, Aaron J. , LeClere, Lance E. , Lee, Cassandra Alda , Levy, Bruce, McAllister, David R. , Medvecky, Michael J. , Owens, Brett D. , Pace, J Lee , Redler, Lauren H. , Rodeo, Scott A. , Sonnery‐Cottet, Bertrand

Orthopaedic Journal of Sports Medicine | February 6, 2026 | Volume: 14 | Issue: 2 | Pages: No page available

10.1177/23259671251380883 | PMID 41660291 Get It

Background: A critical component of conducting systematic reviews or meta-analyses is assessing the methodological quality and bias of included studies. Several methodological quality assessment tools have been developed; however, these tools may not be relevant to observational sports medicine research, which carries numerous unique nuances and biases. Purpose: To develop the Sport Publication Observational Research Tool (SPORT), which evaluates and scores the methodological quality of observational sports medicine research. Study Design: Consensus statement. Methods: SPORT was developed through a modified Delphi approach involving members from the Herodicus Society and The FORUM. All active members were invited to participate in the process aimed at building consensus on SPORT content and scoring. After finalizing SPORT, a power analysis led to the independent selection of 55 observational clinical sports medicine studies, which were scored twice by 4 reviewers of varying training levels. Interrater and intrarater reliability for SPORT was assessed using intraclass correlation coefficients (ICCs). The distribution and percentiles for total SPORT score across the 55 studies were calculated. SPORT was also compared with the methodological index for non-randomized studies (MINORS), a commonly utilized quality assessment tool. Results: A total of 51 members participated and achieved 100%, 100%, 98.0%, and 98.0% completion rates for rounds 1 through 4, respectively. The final SPORT included 19 subscores related to methodological quality and bias and achieved 94% consensus approval. Mean SPORT completion time was 6 minutes and 19 seconds per study, which varied significantly by reviewer training level. The subscore "peer review" demonstrated unacceptable reliability and was removed. The remaining 18 subscores exhibited ICC ranges of 0.599 to 0.955 for interrater reliability and 0.530 to 0.936 for intrarater reliability. Total SPORT score demonstrated excellent agreement, for interrater (ICC, 0.967) and intrarater reliability (ICC, 0.966). Median SPORT score across the 55 studies was 20.0 and skewed toward lower scores. There was a moderate significant correlation between SPORT and MINORS ( r [53] = 0.575; P < .001). Conclusion: An objective tool to assess the methodologic quality of observational sports medicine research (SPORT) was successfully developed through a modified Delphi approach with numerous content experts in the field. This tool may be useful in assessing the methodological quality of primary observational sports medicine studies included in systematic reviews and meta-analyses.
Overcoming Intrapulmonary Shunting: A Case Report of Hepatopulmonary Syndrome Post‐Liver Transplantation Treated With Inhaled Treprostinil
Fanous, John, McNierney, Dakota , Abdalla, Abdelmohaymin , Azar, Jehad

Respirology Case Reports | May 19, 2025 | Volume: 13 | Issue: 5 | Pages: No page available

10.1002/rcr2.70204 | PMID 40391238 Get It

ABSTRACTHepatopulmonary syndrome (HPS) poses a significant challenge in liver transplant recipients, mostly resulting in persistent hypoxaemia postoperatively. We present the case of a 59‐year‐old male with decompensated metabolic dysfunction associated with steatohepatitis (MASH) cirrhosis, who had liver transplantation due to end‐stage liver disease complicated by HPS‐related hypoxaemia. Despite successful transplantation, the patient continued to experience severe hypoxaemia, requiring high supplemental oxygen despite maximal conservative treatment per guidelines. Potential causes for hypoxaemia post‐liver transplant have been excluded; HPS as the sole cause of hypoxaemia was proved with a repeat shunt study, which estimated the shunt at 59%. Treatment with inhaled Treprostinil led to a remarkable improvement in oxygenation, facilitating the successful weaning of oxygen supplementation. The patient's hypoxaemia improved to full recovery upon discharge. This case highlights the persistence of hypoxaemia post‐liver transplantation in HPS patients and underscores the potential role of inhaled Treprostinil as a novel therapeutic approach to address this complication.
Does a Mediastinal Mass Mandate Biopsy? A Case of Esophageal Duplication Cyst ( Atypical Case of Posterior Mediastinal Mass)
Rojas, Carlos A. , Azadeh, Natalya , Azar, Jimmy C. , Chen, Jun , Reeve, M., Azar, J.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7522-A7522

10.1164/ajrccm.2025.211.abstracts.a7522 Get It

Abstract Introduction Mediastinal masses may exhibit various clinical and pathological features. Posterior mediastinal lesions are often neurogenic, followed by lymphadenopathy, extramedullary hematopoiesis, paraspinal abscess, and rarely, foregut duplication cysts (prevalence: 0.122%). Given the rarity and diagnostic challenges, these masses are often biopsied, though may not be ideal. We present a case of esophageal duplication cyst (EDC). Case presentation A 33-year-old woman with mild intermittent asthma, had initially presented to an outside facility for chronic productive cough, episodic chest tightness and dyspnea both at rest and with exertion, inspiratory and expiratory wheezes. Despite multiple courses of prednisone for presumed asthma exacerbation, her symptoms persisted. An initial Computer Tomography (CT) Chest demonstrated a 5 x 4 x 3 cm mass within the visceral mediastinum. Bronchoscopy with endobronchial ultrasound and transbronchial needle aspiration of the mediastinal lymph nodes was nondiagnostic, showing scant lymphocytes and abundant mucin. Broad autoimmune, connective tissue disease, and infectious disease workups were negative, prompting referral to our facility. Physical exam and labs were unremarkable and pulmonary function testing showed no evidence of small airway obstruction. A High-Resolution CT Chest revealed a 3.1 x 3.7 x 4.5 cm noncalcified, well-circumscribed mass soft tissue density, adjacent to the esophagus with elevated Hounsfield units close to esophagus. Ultimately duplication cyst was suspected and Magnetic Resonance Imaging (MRI) with contrast showed high T1 and T2 signal within the lesion and no enhancement after contrast, deemed compatible with proteinaceous/hemorrhagic cyst (Figure 1 A-D). Biopsy was deferred given diagnostic MRI characteristics, and risk of secondary infection. The diagnosis of EDC was confirmed via multidisciplinary thoracic tumor board revision. Ultimately, she was referred for surgical resection. Discussion The incidence of EDC is 1 in 8,200, with a two-fold male prevalence over women. These patients may present with dysphagia, cough, stridor, pain, or arrhythmia since childhood, or may be entirely asymptomatic. EDCs can develop along the esophagus, with 90% lacking communication with the esophageal lumen. Although posterior mediastinal mass typically require biopsy to exclude malignancy, tissue biopsy should be avoided in cases with suspected duplication cyst given risk of infection, abscess formation and mediastinitis. Transesophageal endoscopic ultrasonography could further characterize the cyst, however MRI is considered the gold standard diagnostic modality. Conclusion MRI is the gold standard diagnostic modality of EDC. Biopsy should be avoided given the risk of infection. Clinicians should consider a broad differential for posterior mediastinal mass and avoid unnecessary invasive testing.
Telomere Biology Disorder Presented With De Novo Pneumocystis Jirovecii Pneumonia
Asad, Dayab , Joudeh, Nagham, Reeve, M., Omar, Ahmad Afiq Irshad, Zamora, Ana, Azar, J., Asad, D., Omar, A., Si, L.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A6082-A6082

10.1164/ajrccm.2025.211.abstracts.a6082 Get It

Abstract Background Pneumocystis jirovecii pneumonia (PJP) is commonly seen in immunocompromised patients. Telomere biology disorder (TBD), which is a genetic disorder marked by mutations in telomere-maintenance genes, leading to shortened telomere, accelerated aging, and multi-systems effects including the pulmonary and immune systems. Idiopathic pulmonary fibrosis (IPF) is the most common pulmonary manifestation in TBD. Opportunistic infections, such as PJP, occurring de novo are rare in TBD, presenting unique diagnostic and therapeutic challenges. Case Presentation We present a female in her seventies with chronic dry cough and exertional dyspnea referred for evaluation of interstitial lung disease (ILD). Her family history revealed early-onset pulmonary fibrosis in her mother and sister. A year before the presentation, she developed acute hypoxic respiratory failure with bilateral pulmonary infiltrates. Bronchoalveolar lavage confirmed PJP despite no established immunosuppression. She received Bactrim and prednisone without clinical improvement. High-resolution chest CT revealed progressive infiltrates and fibrotic lung disease. Surgical lung biopsy showed organizing pneumonia, diffuse alveolar damage, and fibrosis, consistent with probable usual interstitial pneumonia (UIP). Ultimately, she developed rapidly progressive ILD. Further evaluation ruled out autoimmune and connective tissue disease. Telomere studies confirmed TBD, with her lymphocyte and granulocyte telomere lengths between the 1st and 10th percentiles. (figure1) Genetic testing is underway for familial pulmonary fibrosis. Discussion This case illustrates a rare presentation of PJP de novo in a patient with TBD, highlighting opportunistic infections risk in those patients without immunosuppression and before transplantation. TBD results in quantitative and qualitative T-cell immunodeficiency, reducing CD4+ T-cell count, predisposing to opportunistic infections, including PJP. TBD patients often experience a rapidly progressive course of ILD due to inherited telomere dysfunction causing limited regenerative capacity of Alveolar epithelial type 2 cells (AEC2s) exacerbated by environmental or age-related factors such as oxidative stress or smoking. Management requires a multidisciplinary approach with early genetic testing, antifibrotic therapies, and prophylactic treatments to prevent infections. This case underscores the importance of considering TBD in patients with opportunistic infections like PJP in the absence of traditional immunosuppressive risk factor and in patients with premature or progressive pulmonary fibrosis. Conclusion Telomere biology disorder can present with rapidly progressive ILD with atypical infections like PJP while on immunosuppression. To the best of our knowledge de novo PJP pneumonia in patient with TBD is unreported in the literature. High clinical suspicion, quantitative CD4 evaluation and consideration of PJP prophylaxis prevent an otherwise fatal outcome. Figure1:
Rheumatoid Arthritis Pleural Lung Disease Mimicking Empyema
Asad, Dayab , Joudeh, N., McNierney, Dakota , D’Cunha, Jonathan, Sakata, Kenneth K. , Azar, J., Asad, D., Joudeh, N., Nagaraja, Vivek

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5936-A5936

10.1164/ajrccm.2025.211.abstracts.a5936 Get It

Abstract Introduction Rheumatoid arthritis (RA) is a systemic autoimmune rheumatic disease (SARD) primarily associated with articular involvement, but is often associated with lung involvement, sometimes preceding articular symptoms. Common pulmonary manifestations include interstitial lung disease (ILD), airway, and serosal involvement. RA-related pleural disease can mimic empyema due to the pleural fluid's green, pus-like appearance, exudative nature, low pH, markedly low glucose, and elevated lactate dehydrogenase (LDH) levels. Empyema sometimes yields negative cultures which can accentuate the diagnostic challenge in such cases. This report presents a patient with RA-related pleural lung disease who was referred to our hospital with trapped lung presumed to be secondary to empyema in the setting of pleural-based pulmonary abscess. Case Report A 66-year-old female with a 22-year history of RA presented with recurrent right-sided pleural effusions and progressive dyspnea over three years. Her initial presentation in 2022 involved a large right-sided pleural effusion, suspected to result from a ruptured pleural-based pulmonary abscess that led to empyema and subsequently a trapped lung. Pleural fluid analysis showed elevated LDH (1364 U/L), low glucose (45 mg/dL), high cholesterol (121 mg/dL), and low triglycerides (79 mg/dL). Due to refractory exudative effusion and a comprehensive negative infectious evaluation (bacterial, mycobacterial, and fungal cultures), RA-related pleural disease was suspected. The patient underwent video-assisted thoracoscopic surgery (VATS), which revealed pleural-based rheumatoid nodules and pleural thickening. (figure1) Lung and pleural biopsies confirmed RA-associated fibrinous pleuritis, RA-associated follicular bronchiolitis, and usual interstitial pneumonitis. Given the complexity of the infection, a thoracotomy with decortication and pleurectomy was planned and conducted in stages. Immunosuppressive regimen was switched from leflunomide to rituximab. Discussion This case underscores the diagnostic complexity in distinguishing RA-associated pleural effusion from empyema. Features such as pleural nodularity resembling a pulmonary abscess, unilateral exudative effusion, grossly purulent pleural fluid, low pH and glucose, and elevated LDH levels led to an initial misdiagnosis of empyema. Characteristic pleural fluid, along with persistent negative cultures and absence of sepsis pointed towards RA-related pleural disease. VATS and biopsy were instrumental in establishing the final diagnosis through characteristic histopathological findings of RA-associated pleural, parenchymal and airway involvement. Conclusion For RA patients with pleural effusion suggestive of empyema, especially in the context of negative cultures and no signs of sepsis, RA-related pleural disease should be a consideration. Early recognition and timely immunosuppressive therapy escalation can prevent complications such as trapped lungs and reduce the necessity for extensive surgical interventions. Figure1:
Unilateral Pulmonary Venous Atresia – The Chronic Thromboembolic Pulmonary Disease Mimicker
Joudeh, Nagham, Asad, Dayab , D’Cunha, Jonathan, Azadeh, Natalya , Rojas, Carlos Rodríguez , Azar, J., Asad, D., Rojas, C., Chen, Jun

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A2208-A2208

10.1164/ajrccm.2025.211.abstracts.a2208 Get It

Abstract Introduction Unilateral pulmonary vein atresia (UPVA) is a rare congenital anomaly involving absent or obstructed pulmonary veins (PV), often leading to chronic pulmonary venous stasis, recurrent infections, and hemoptysis. Although typically diagnosed in infancy, UPVA can present in adulthood. This report presents a 63-year-old male referred as a case of chronic thromboembolic pulmonary disease (CTEPD) who was diagnosed with UPVA. We describe the diagnostic complexities and potential explanation for loss of pulmonary artery (PA) perfusion in such cases. Case Presentation A 63-year-old man was referred to rule out CTEPD. His past medical history included coronary artery disease and sleep apnea. He presented with chronic cough, repeated hemoptysis, recurrent pneumonias requiring prolonged antibiotics use, and progressive exertional dyspnea. Physical examination was unremarkable. Pulmonary function tests showed moderate restriction and moderately-reduced diffusion capacity. A ventilation-perfusion (V/Q) scan revealed complete absence of perfusion in the left lung. [figure1] High-resolution CT revealed a straight left atrial border sign with absent left superior and inferior PVs, left pulmonary arterial tree hypoplasia, hypoplastic left lung with fibrotic changes due to chronic venous-lymphatic engorgement and pulmonary hypoperfusion. CT also showed compensatory right lung hyperinflation and bronchial artery collaterals. Echocardiography indicated an atrial septal defect (ASD) with no pulmonary vascular disease. Based on CT angiography, UPVA was considered the leading diagnosis. Discussion UPVA is a congenital disease rarely presenting in adulthood with recurrent infections, hemoptysis, and fibrosis. It often accompanies congenital cardiac conditions, like ASD in our case. Pulmonary angiography may reveal ipsilateral PA hypoplasia and atrophied peripheral vessels. The absence of perfusion in the V/Q scan could be explained by reversed blood flow in the PA from congestion caused by the atretic PVs and ipsilateral backflow from the bronchial arteries collaterals. Differential diagnosis like CTEPD was excluded due to atypical complete loss of perfusion of the left lung, and lack of the other radiological stigmata. Swyer-James-MacLeod syndrome was excluded due to a mismatched perfusion defect. Proximal Interruption of the PA was also excluded due to normally developed proximal left and right PAs. Imaging is crucial in showing absent PVs and hypoplastic ipsilateral lung. Conservative management for UPVA is recommended. Given recurrent infections and hemoptysis, pneumonectomy can be considered. Conclusion This case illustrates the atypical presentation of UPVA as a CTEPD mimicker, presenting with absent pulmonary perfusion unilaterally, which can be explained by reversed pulmonary flow secondary to venous engorgement and backflow from bronchial artery collaterals. Figure1:
A mixed-methods study assessing the performance of a clinical decision support tool for Clostridioides difficile testing for patients receiving laxatives
Peaper, David R. , Rathod, Shardul N , Sussman, L. Scott , Azar, Marwan M. , Murdzek, Christina, Roberts, Scott C. , Tichy, Eric M. , Topal, Jeffrey , Kashyap, Nitu , McManus, Dayna , Topal, Jeffrey E , Martinello, Richard A , Azar, Marwan M

Infection Control & Hospital Epidemiology | March 13, 2025 | Volume: 46 | Issue: 5 | Pages: 497-503

10.1017/ice.2025.30 | PMID 40079209 Get It

Abstract Objective: To better understand clinicians’ rationale for ordering testing for C. difficile infection (CDI) for patients receiving laxatives and the impact of the implementation of a clinical decision support (CDS) intervention. Design: A mixed-methods, case series was performed from March 2, 2017 to December 31, 2018. Setting: Yale New Haven Hospital, a 1,541 bed tertiary academic medical center. Participants: Hospitalized patients ≥ 18 years old, and clinicians who were alerted by the CDS. Intervention: CDS was triggered in real-time when a clinician sought to order testing for CDI for a patient who received one or more doses of laxatives within the preceding 24 hours. Results: A total of 3,376 CDS alerts were triggered during the 21-month study period from 2,567 unique clinician interactions. Clinicians bypassed the CDS alert 74.5% of the time, more frequent among residents (48.3% bypass vs. 39.9% accept) and advanced practice providers (APPs) (34.9% bypass vs. 30.6% accept) than attendings (11.3% bypass vs. 22.5% accept). Ordering clinicians noted increased stool frequency/output (48%), current antibiotic exposure (34%), and instructions by an attending physician to test (28%) were among the most common reasons for overriding the alert and proceeding with testing for CDI. Conclusions: Testing for CDI despite patient laxative use was associated with an increased clinician concern for CDI, patient risk for CDI, and attending physician instruction for testing. Attendings frequently accepted CDS guidance while residents and APPs often reinstated CDI test orders, suggesting a need for greater empowerment and discretion when ordering tests.
Clinical profile and response to adjuvant treatments in patients with follicular dendritic cell sarcoma in the United States: Insights from SEER analysis.
Yadav, Sumeet Kumar, Hussein, Guleid , Azar, Ibrahim , Yadlapalli, Sri , Krishnamoorthy, Geetha , Goodman, Judie R. , Vojjala, Nikhil , Aldecoa, Kim Abbegail Tan , Liu, Bolun

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e23537-e23537

10.1200/jco.2024.42.16_suppl.e23537 Get It

e23537 Background: Follicular Dendritic Cell Sarcoma (FDCS) is a rare, indolent, low-grade sarcoma known for local recurrences managed primarily by surgery. The role for adjuvant therapy has not been established for either radiation or chemotherapy. We aimed to comprehensively analyze clinical and epidemiological profiles and responses to treatment in these patients. Methods: This is a retrospective study using the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Result (SEER) database. Cases of FDCS between 2001 to 2022 were identified utilizing the International Classification of Diseases for Oncology edition 3 (ICD-O-3) code 9758/3. Only adults > 18 years of age and diagnosed by positive histology or cytology were included. Descriptive statistics were used to describe demographic and tumor characteristics. Logistic regression was used to identify the factors influencing survival. Kaplan-Meier method was used to plot survival based on different treatment regimens and stages. Results: A total of 168 patients with FDCS were identified, with more than 50% of the patients ≥ 50 years of age. The mean age at diagnosis was 52.6 years, 56% were female, and 74.4% were white. Most of the patients had localized disease (63.7%), 17.9% had distant disease, and the remaining had unknown stages. About 90% of the patients underwent surgery, with 41% receiving local tumor excision. In Univariate analysis, older age, and distant disease were found to have poor outcomes. Surgery, irrespective of stage, was found to improve overall Survival (Table 1). While chemotherapy and distant disease had poor outcomes in univariate analysis, they were not statistically significant in multivariate analysis. The majority of the patients who received chemotherapy alone without surgical intervention had distant disease, explaining the poor outcome seen in univariate analysis. Among 107 patients with localized disease, 41 patients (41.1%) underwent only surgery and 43 patients (40.1%) received adjuvant therapy (either chemotherapy or radiation vs both) along with surgery. 5-year overall survival was significantly lower in patients who received adjuvant therapy. (88.4% vs 68.4%, p = 0.001). Conclusions: In conclusion, FDCS has a fair overall 5-year survival with surgery alone. Patients with localized disease, who received adjuvant therapies had poor survival outcomes as compared to the surgery-only group owing to disease burden. Large prospective studies are required to properly evaluate the benefit of adding chemotherapy or radiotherapy in resectable disease.
Invasive Cardiopulmonary Exercise Testing Phenotypes of Chronic Thromboembolic Pulmonary Vascular Disease
Kirupaharan, Pradhab , Azar, J., Wang, Xiaofeng , Wang, Y., Tonelli, Adriano R. , Heresi, Gustavo A.

D105. BALBOA PARK EXPLORERS: TRANSLATIONAL SCIENCE AND EPIDEMIOLOGY IN PH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7367-A7367

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7367 Get It

Efficacy and safety of tranexamic acid in the management of chronic subdural hematoma: a systematic review and meta-analysis
Salim, Hamza , Adeeb, Nimer , Spellicy, Samantha , Abdelgadir, Jihad , Guthikonda, Bharat , Azar, Jehad , Salim, Hamza , Musmar, Basel , Orscelik, Atakan , Cuellar, Hugo , Jabbour, Pascal , Hasan, David

Journal of Neurosurgery | April 5, 2024 | Volume: 141 | Issue: 4 | Pages: 945-954

10.3171/2024.1.jns232463 | PMID 38579356 Get It

OBJECTIVE Chronic subdural hematoma (CSDH) is a prevalent neurosurgical condition, particularly among the elderly. Various treatment options exist, but recurrence rates remain high. This systematic review and meta-analysis aims to assess the efficacy and safety of tranexamic acid (TXA) in the management of CSDH. METHODS The authors conducted a comprehensive literature search adhering to the 2020 PRISMA guidelines, involving three primary databases (Scopus, PubMed, and Web of Science) that were searched for articles compiled from inception until October 20, 2023. The primary outcome was recurrence of CSDH, and secondary outcomes included complications and SDH volume following TXA treatment. The mean difference and odds ratios with 95% confidence intervals were calculated using the random-effects model. RESULTS A total of 5 studies, involving 643 patients in the TXA group and 736 patients in the non-TXA group, met the inclusion criteria. The meta-analysis revealed that TXA use led to a significantly lower CSDH recurrence (OR 0.35, 95% CI 0.23–0.53; p < 0.01) without increasing complications (OR 1.84, 95% CI 0.43–7.95; p = 0.42). Additionally, TXA users had a significantly lower CSDH volume compared to the non-TXA group at 3-month follow-up (mean difference −4.56, 95% CI −8.76 to −0.36; p = 0.03). CONCLUSIONS The findings suggest that TXA might be a promising agent for reducing the risk of CSDH recurrence without elevating the risk of complications. However, these results should be interpreted cautiously due to the limited number of studies included and the methodological heterogeneity. Further large-scale randomized controlled trials are needed to confirm these findings.